StemCell Therapy

Photo credit: NBC - Getty Images

From Woman's Day

On Tuesday, Todays Al Roker announced he would be undergoing total shoulder replacement surgery. The NBC weatherman said hes been living with intense pain in his right shoulder due to arthritis, a general term for a range of conditions that cause swelling, pain, and stiffness in or around a joint.

According to the Centers for Disease Control and Prevention, 1 in 4 Americans have arthritis, and its typically treated with medication or surgery to repair the joint or manage symptoms.

The arthritis in Al's right shoulder has caused pain and affected his range of motion, particularly his ability to move his shoulder up and down. Its not bad during the day, but at night its an intense pain that literally wakes me up. For the last month, Ive only been sleeping about two or three hours a night, which even for me is a little bit less, Al said on the 3rd hour of Today. Its gotten to the point where I cant even sleep at night.

Al, who said his moms side of the family suffers from really intense arthritis, has osteoarthritis, the most common form of the condition. Osteoarthritis occurs when the protective cartilage that cushions the bones begins to wear down over time, causing pain and joint damage.

The surgery will be Al's second shoulder surgery in six years, after he had his rotator cuff repaired in his left shoulder in 2014. The procedure also marks Rokers second procedure in less than a year, as the Today host had hip replacement surgery in September 2019. The deal is that Im going to have replaced everything by 2027, Al joked.

Al's doctor, Riley Williams III, M.D., an orthopedic surgeon at the Hospital for Special Surgery, told Today that the surgery is designed to restore the normal joint services so that arthritic, achy pain that hes been having and waking him up at night can go away, and we can kind of get him back on a road to recovery.

Story continues

What you can expect after having a shoulder replacement is 25-plus years of really good function, provided you do all the requisite things after surgery [like] getting good healing, good nutrition and physical therapy to re-strengthen the muscles around the shoulder, Williams added. It really, really is life-changing and can bring you back to a point where you dont even realize that you had the shoulder operated on in the first place.

Al will not host Today this week as he recovers, and he will likely be in a sling for the next three weeks. He will also undergo physical therapy in the days after his procedure.

Want more entertainment news? You're in luck! Sign up for our FREE newsletter for even more of the Woman's Day content you want.

You Might Also Like

See the original post here:
Al Roker Will Have Total Shoulder Replacement Surgery Due to Intense Arthritis Pain - Yahoo Lifestyle

Emphasising the point, a study published in the Oxford Journal of Rheumatology stated that 41 percent of those suffering from rheumatoid arthritis improved on a gluten-free diet conducted over a one year period.

According to Peyton, you should go easy on steak if you are looking to avoid a flare up.

She explained: "Whilst there are fats that send out anti-inflammatory messages, there are also fats that can create pro-inflammatory messages in the body. These typically come from animal fats."

"We all require the ability to create some inflammation when there is a need to heal (after an injury for example)."

However, as Peyton pointed out, the ratio of inflammatory fats is too high in the typical Western diet.

"Therefore take a look at your diet and assess whether you are consuming sufficient anti-inflammatory fats and not too many pro-inflammatory fats. It is all about the balance," she said.

According to the NHS, if you feel your arthritis is aggravated by eating certain foods, it may be useful to try avoiding problematic foods for a few weeks to see if your symptoms improve.

"But it's important to ensure your overall diet is still healthy and balanced," the healthy body says.

A Mediterranean-style diet, which is based on vegetables, fruits, legumes, nuts, beans, cereals, grains, fish and unsaturated fats such as olive oil, is recommended.

According to the NHS, there's some evidence to suggest that taking fish oil supplements may help reduce joint pain and stiffness caused by rheumatoid arthritis.

Eating a healthy diet can also help to maintain a healthy weight.

According to the National Rheumatoid Arthritis Society (NRAS), excess weight is bad for joints and overall health.

Original post:
Rheumatoid arthritis: The healthy bread alternative that could be making symptoms worse - Express

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about the effect of rheumatic diseases on COVID-19 severity, virtual computer-assisted preoperative planning in hip fracture, racial disparities in psoriatic arthritis, and fatigue in rheumatic diseases.

Hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, according to a recent study, but inflammatory arthritis (IA) may not have the same effect. Final analysis included 456 patients each in rheumatic and non-rheumatic groups. In the rheumatic disease cohort, 60% of patients had IA, and 40% had connective tissue disease. About three-quarters of patients (74%) were hospitalized. The risk of severe COVID-19 was 31.6% in the rheumatic cohort and 28.1% in the non-rheumatic cohort. In bivariate analysis, factors associated with increased COVID-19 severity risk in the rheumatic group were aging; male sex; and previous comorbidity including obesity, diabetes, hypertension, or cardiovascular or lung disease. Upon logistic regression analysis, the factors independently associated with severe COVID-19 disease were increased age, male sex, and connective tissue disease.

An estimated 300,000 hip fractures occur in the U.S. each yeara number that is expected to double with the aging population. About half of hip fractures are intertrochanteric fractures, but postoperative outcomes tend to be poor, including a high risk of mortality as well as poorer functional and quality of life outcomes. Certain risk factors for such poor outcomes are age and sexwhich cannot be modified. One thing that can be modified, though, is preoperative planning. And according to a study, computer-assisted virtual planning in cases of intertrochanteric hip fracture may improve postoperative complications, including mortality risk.

A study observed how ethnicity may affect disease expression of psoriatic arthritis (PsA), observing differences between patients of South Asian (SA) versus North European (NE) descent. They concluded that SA patients may have poorer clinical outcomes and be more adversely affected by PsA disease than NE patients.

IA patients often experience fatigue; 41% to 51% of rheumatoid arthritis, PsA, and spondyloarthritis patients suffer from severe fatigue. Patients with these rheumatic diseases who are plagued by fatigue may suffer in several domains, including quality of life, work impairment, depression, and more, according to a new study.

Here is the original post:
Rheum Round-up: Rheumatic Disease and COVID-19 Severity, Improving Hip Fracture Outcomes, and more - DocWire News

Hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, according to a recent study, but inflammatory arthritis may not have the same effect.

Since severe COVID-19 is associated with a hyperinflammatory process, it is of particular interest to investigate how pre-existing inflammatory diseases or the previous use of immunosuppressive agents influence COVID-19 expression, the study authors explained.

The researchers identified PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis) or connective tissue diseases (including systemic lupus erythematosus, Sjgrens syndrome, systemic sclerosis, polymyalgia rheumatica, and vasculitides) and compared them 1:1 to non-rheumatic controls matched based on age, sex, and PCR date. The primary outcome was severe COVID-19 (death, invasive ventilation, intensive care unit admission, or serious complications). The correlation between severe COVID-19 and potential prognostic variables was evaluated, adjusting for COVID-19 treatment.

Final analysis included 456 patients each in the rheumatic and non-rheumatic groups. Both cohorts had a mean ae of 63 years and were 41% male. In the rheumatic disease cohort, 60% of patients had inflammatory arthritis, and 40% had connective tissue disease. About three-quarters of patients (74%) were hospitalized. The risk of severe COVID-19 was 31.6% in the rheumatic cohort and 28.1% in the non-rheumatic cohort. In bivariate analysis, factors associated with increased COVID-19 severity risk in the rheumatic group were aging; male sex; and previous comorbidity including obesity, diabetes, hypertension, or cardiovascular or lung disease. Upon logistic regression analysis, the factors independently associated with severe COVID-19 disease were increased age (odds ratio [OR]=4.83; 95% confidence interval [CI], 2.78 to 8.36), male sex (OR=1.93; 95% CI, 1.21 to 3.07), and connective tissue disease (OR=1.82; 95% CI, 1.00 to 3.30).

The researchers stated in their conclusion that among hospitalised patients with inflammatory rheumatic diseases, having a [connective tissue disease] pose[s] a significantly greater risk for poor outcomes, whereas immunosuppressive therapies do not. Previously known risk factors as ageing and male sex also apply to patients with rheumatic diseases. This observation should help to tailor recommendations to specific diagnostic and therapeutic groups of patients with rheumatic diseases during this or future coronavirus pandemics.

The study was published in Annals of the Rheumatic Diseases.

Read more here:
Do Inflammatory and Autoimmune Rheumatic Diseases Affect COVID-19 Illness Severity? - DocWire News

A model incorporating gene expression and clinical factors predicts response to anti-tumor necrosis factor (TNF) therapy in patients with rheumatoid arthritis (RA), according to study results published in Network and Systems Medicine.

Rheumatoid arthritis is a complex disease and the molecular factors that predict response to treatment are poorly understood. Using gene expression data from patients receiving anti-TNF therapy, investigators aimed to build a biomarker panel, which predicts response to anti-TNF therapies in patients with RA.

Using publicly available data, a comprehensive map of the human protein-protein interactome was generated and used to identify an RA disease module, which contained approximately 200 proteins. Within this module, 66% of the proteins had been previously linked to RA in genome-wide association studies, and the remaining were significantly enriched in similar Gene Ontology biological processes.

Microarray data were obtained from the Gene Expression Omnibus database for 58 women receiving anti-TNF therapy. Using a random forest machine-learning algorithm, the data were used to identify genes for which expression was predictive of response and nonresponse to therapy. Based on the microarray profile and the RA disease module, 37 genes were identified as discriminatory biomarkers for anti-TNF response.

In addition, RNA sequencing (RNAseq) data were obtained for 143 patients with RA from the Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study. In addition to gene expression, RNAseq data enabled the identification of single-nucleotide variations (SNVs; formerly single-nucleotide polymorphisms) that were associated with treatment response. An additional 22 SNVs, which were associated with the RA disease model, were identified that were linked to response to anti-TNF therapy.

With the inclusion of clinical factors, a total of 70 biomarkers were identified and used to train a machine-learning algorithm to predict response to anti-TNF therapy. The final model generated, which predicted nonresponse to anti-TNF therapy, consisted of 10 SNPs, 8 gene transcripts, 2 laboratory tests, and 3 clinical measures.

To confirm that the model was broadly generalizable, data from an independent group of 175 patients from the CERTAIN study were used for a validation trial. Patients who were identified by the model as being nonresponders to anti-TNF therapy were 6.57-times more likely to be a true nonresponder than a responder (95% CI, 2.75-15.70). The model predicted nonresponse to therapy with a positive predictive value of 89.7% (95% CI, 79.0-95.7%), a specificity of 86.8% (95% CI, 72.4-94.1%), and a sensitivity of 50.0% (95% CI, 40.8-58.7%). There was no significant difference observed in the predictive power of the model based on ethnicity.

When the relevant gene transcripts and SNVs were mapped to the human interactome, they were all within close proximity to the RA disease module as well as established RA drug targets, including Janus kinase and TNF-. Pathway enrichment identified genes involved in T-cell signaling as the most enriched pathway in the biomarkers associated with a therapeutic response.

Customization of treatment regimens to match the individualized disease biology of each patient is a goal of modern medicine, the researchers concluded. Development and validation of a drug response algorithm that predicts nonresponse to a targeted therapy using this machine-learning and network medicine approach show great promise for advancing precision medicine in the treatment of RA and other complex autoimmune diseases where costly therapeutic interventions are met with inadequate patient response.

Disclosure: This study was supported by Scipher Medicine Corporation. Please see the original reference for a full list of authors disclosures.

Mellors T, Withers JB, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Network and Systems Medicine. 2020;3(1):91-104.

Continue reading here:
Clinically Validated Blood-Based Test Predicts Response to Anti-TNF Therapies in RA - Rheumatology Advisor

Tulsi or holy basil is loaded with several health benefits. You can prepare tulsi tea to fight various ailments. Read here to know some notable health benefits of drinking tulsi tea.

Drinking tulsi tea can help you boost immunity

Holy basil or tulsi is a part of almost every Indian household. This auspicious plant is loaded with several amazing health benefits too. Holy basil has a strong taste and aroma and can be added to your diet in several ways. One of the healthiest ways to add holy basil to your diet is by preparing tulsi tea. If you are a tea lover, you should definitely try tulsi tea to reap the health benefits these leaves can offer. If you are curious to know the benefits of tulsi tea, keep reading to know these.

Tulsi tea has a positive effect on your mental health. Drinking this tea leaves a soothing effect that can help you relieve stress. Studies also suggest that it can help you control symptoms of anxiety.

Drinking tulsi tea can help you beat stress effectivelyPhoto Credit: iStock

Holy basil helps in controlling inflammation and joint pain. These are the two common symptoms of arthritis. Therefore, drinking tulsi tea can help in controlling arthritis symptoms.

Also read:Arthritis Diet: Foods You Should Avoid To Control Inflammation

Tulsi leaves are loaded with anti-microbial properties which can help you promote overall oral health. This tea can help control harmful bacteria and germs in the mouth.

Studies suggest that tulsi is beneficial in controlling blood sugar levels and other symptoms of type-2 diabetes.

Also read:Diabetes Diet: Know How Many Almonds You Should Eat To Lower Blood Sugar Levels

Bad cholesterol levels are linked with a higher risk of heart disease. Adding tulsi to your diet can help in controlling bad cholesterol levels.

Tulsi tes is beneficial for your heart health as it helps control cholesterol levelsPhoto Credit: iStock

Tulsi is one of the herbs which can help you boost immunity. Aa sting immunity system will help you fight against illness effectively.

Preparing tulsi tea is quite simple. You can boil some tulsi leaves in one to two cups of water. Add ginger to enhance the taste of the tea. Boil the mixture properly. After some time, strain the tea and add lemon and honey to enhance the taste.

Promoted

Also read:How Many Cups Of Green Tea Should You Drink Per Day? Know The Side Effects Of Drinking Too Much Green Tea

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

DoctorNDTV is the one stop site for all your health needs providing the most credible health information, health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like diabetes, cancer, pregnancy, HIV and AIDS, weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.

Read more:
Holy Basil: Know The Many Health Benefits Of Drinking Tulsi Tea - Doctor NDTV

The Rheumatoid Arthritis Diagnosis Tests market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Our analysts monitoring the situation around the Globe explain that after COVID-19 crisis the market will generate remunerative prospects for producers. The goal of the report is to provide a further illustration of the current scenario, economic slowdown and effect of COVID-19 on the industry as a whole.

Global Rheumatoid Arthritis Diagnosis Tests Market is valued at USD 529.4 Million in 2018 and expected to reach USD 822.7 Million by 2025 with a CAGR of 6.5% over the forecast period. Increasing geriatric population globally is anticipated to drive growth of Global Rheumatoid Arthritis Diagnosis Tests Market.

Rheumatoid arthritis is a long-term, progressive and disabling autoimmune disease (as in this condition a persons immune system mistakes the bodys healthy tissues for foreign invaders). It is also a systemic disease, which means it affects the whole body. It causes inflammation, swelling, and pain in and around the joints and other body organs. It most commonly affects the hands and feet first, but it can occur in any joint. Its major symptoms includes; pain, swelling, and stiffness in more than one joint, symmetrical joint involvement, joint deformity, unsteadiness when walking, a general feeling of being unwell, fever, loss of function and mobility, weight loss, weakness and others. There are several different types of rheumatoid arthritis, some of them are seropositive RA, seronegative RA and JIA (juvenile idiopathic arthritis). It affects adults of any age, although most people are diagnosed between the ages of 40 and 60 and it is two to three times more common among women than men. A diagnosis of rheumatoid arthritis is based on the patients symptoms, a physical examination and the results of x-rays, scans and blood tests.

Global rheumatoid arthritis diagnosis tests market report is segmented on the basis of type, end-user and region & country level. Based upon type, global rheumatoid arthritis diagnosis tests market is classified into serology tests and monitoring rheumatoid arthritis treatment efficiency tests. The serology tests segment is further categorized into erythrocyte sedimentation rate, anti-cyclic citrullinated peptide, rheumatoid factor, antinuclear antibody, uric acid and others. The monitoring rheumatoid arthritis treatment efficiency tests segment is further categorized into muscle enzyme tests, salicylate level count and creatinine test. Based upon end-user, global rheumatoid arthritis diagnosis tests market is divided into hospitals, diagnostics laboratories and ambulatory surgical centers.

The regions covered in this Rheumatoid Arthritis Diagnosis Tests Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of rheumatoid arthritis diagnosis tests is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Scope Of The Report:Report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Rheumatoid Arthritis Diagnosis Tests Market.

Key Benefits for Rheumatoid Arthritis Diagnosis Tests Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

Rheumatoid Arthritis Diagnosis Tests Market Segmentation:By Type: Serology Tests o Erythrocyte Sedimentation rate o Anti-Cyclic Citrullinated Peptide o Rheumatoid Factor o Antinuclear Antibodyo Uric Acido Others Monitoring Rheumatoid Arthritis Treatment Efficiency Tests o Muscle Enzyme Tests o Salicylate Level Counto Creatinine TestBy End-User: Hospitals Diagnostics Laboratories Ambulatory Surgical Centers By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

Rheumatoid Arthritis Diagnosis Tests Market Key Players:Antibodies Inc.Euro Diagnostica ABQiagen NVSiemens Healthcare GmbHBio Rad Laboratories Inc.Genway Biotech, Inc.Abbott DiagnosticsBeckman Coulter, Inc.F. Hoffmann-La Roche Ltd.Thermo Fisher Scientific Incothers.

This comprehensive report will provide: Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.Our Market Research Solution Provides You Answer to Below Mentioned Question: Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

Table of Content1 Study Coverage1.1 Rheumatoid Arthritis Diagnosis Tests Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Rheumatoid Arthritis Diagnosis Tests Market Size2.1.1 Global Rheumatoid Arthritis Diagnosis Tests Revenue 2014-20252.1.2 Global Rheumatoid Arthritis Diagnosis Tests Production 2014-20252.2 Rheumatoid Arthritis Diagnosis Tests Growth Rate (CAGR) 2020-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio2.3.2 Key Rheumatoid Arthritis Diagnosis Tests Manufacturers2.3.2.1 Rheumatoid Arthritis Diagnosis Tests Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Rheumatoid Arthritis Diagnosis Tests Product Offered2.3.2.3 Date of Manufacturers Enter into Rheumatoid Arthritis Diagnosis Tests Market2.4 Key Trends for Rheumatoid Arthritis Diagnosis Tests Markets & Products

3 Market Size by Manufacturers3.1 Rheumatoid Arthritis Diagnosis Tests Production by Manufacturers3.1.1 Rheumatoid Arthritis Diagnosis Tests Production by Manufacturers3.1.2 Rheumatoid Arthritis Diagnosis Tests Production Market Share by Manufacturers3.2 Rheumatoid Arthritis Diagnosis Tests Revenue by Manufacturers3.2.1 Rheumatoid Arthritis Diagnosis Tests Revenue by Manufacturers (2014-2020)3.2.2 Rheumatoid Arthritis Diagnosis Tests Revenue Share by Manufacturers (2014-2020)3.3 Rheumatoid Arthritis Diagnosis Tests Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Rheumatoid Arthritis Diagnosis Tests Production by Regions4.1 Global Rheumatoid Arthritis Diagnosis Tests Production by Regions4.1.1 Global Rheumatoid Arthritis Diagnosis Tests Production Market Share by Regions4.1.2 Global Rheumatoid Arthritis Diagnosis Tests Revenue Market Share by Regions4.2 North America4.2.1 North America Rheumatoid Arthritis Diagnosis Tests Production4.2.2 North America Rheumatoid Arthritis Diagnosis Tests Revenue4.2.3 Key Players in North America4.2.4 North America Rheumatoid Arthritis Diagnosis Tests Import & Export4.3 Europe4.3.1 Europe Rheumatoid Arthritis Diagnosis Tests Production4.3.2 Europe Rheumatoid Arthritis Diagnosis Tests Revenue4.3.3 Key Players in Europe4.3.4 Europe Rheumatoid Arthritis Diagnosis Tests Import & Export4.4 China4.4.1 China Rheumatoid Arthritis Diagnosis Tests Production4.4.2 China Rheumatoid Arthritis Diagnosis Tests Revenue4.4.3 Key Players in China4.4.4 China Rheumatoid Arthritis Diagnosis Tests Import & Export4.5 Japan4.5.1 Japan Rheumatoid Arthritis Diagnosis Tests Production4.5.2 Japan Rheumatoid Arthritis Diagnosis Tests Revenue4.5.3 Key Players in Japan4.5.4 Japan Rheumatoid Arthritis Diagnosis Tests Import & Export

5 Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1 Global Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1.1 Global Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.1.2 Global Rheumatoid Arthritis Diagnosis Tests Consumption Market Share by Regions5.2 North America5.2.1 North America Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.2.2 North America Rheumatoid Arthritis Diagnosis Tests Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.3.2 Europe Rheumatoid Arthritis Diagnosis Tests Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Rheumatoid Arthritis Diagnosis Tests Consumption by Application5.4.2 Asia Pacific Rheumatoid Arthritis Diagnosis Tests Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Top Trending Reports:

https://www.1077yesfm.com/story/42489057/contact-center-software-market-size-shares-and-strategies-for-key-industry-players-by-2025

https://www.1077yesfm.com/story/42489058/coal-bed-methane-market-size-top-key-players-g3-exploration-igas-energy-great-eastern-energy-corporation-ltd-black-diamond-energy-inc-oil-and-natural

https://www.1077yesfm.com/story/42489055/smart-agriculture-market-size-by-top-key-players-deere-company-trimble-agco-agjunction-raven-industries-delavai-ag-leader-technology

https://www.1077yesfm.com/story/42489111/offshore-wind-energy-market-foreseen-to-grow-exponentially-over-forecast-2020-2025-bmrc

Top Trending Reports:

https://www.marketwatch.com/press-release/continuous-glucose-monitoring-market-size-share-cgm-market-analysis-and-forecast-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/global-data-center-market-size-share-2019-analysis-segmentation-market-scenario-and-forecast-to-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/bug-bounty-platforms-market-size-global-trends-market-share-and-market-forecast-2020-to-2027-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/global-body-contouring-market-size-growth-shares-challenges-opportunities-and-forecast-to-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/blood-plasma-products-market-size-share-key-players-trends-detailed-analysis-and-forecast-to-2025-2020-08-12?tesla=y

Go here to read the rest:
Rheumatoid Arthritis Diagnosis Tests Business opportunity 2020 Sales Revenue Analysis, Major Manufacturers Performance, Industry Share and Forecast...

Methotrexate (MTX) monotherapy may be insufficient for achieving sustained minimal disease activity in patients with psoriatic arthritis (PsA), according to study data published in RMD Open. In a cohort of patients with PsA who were initiated with MTX, only 18% maintained minimal disease activity over 1 year of treatment. Methotrexate nonresponders vs responders were more likely to have interleukin (IL)-23-driven disease.

Investigators abstracted data from the Dutch Southwest Early Psoriatic Arthritis Cohort (DEPAR) study collected between 2013 and 2018. The DEPAR enrollees with oligoarthritis or polyarthritis who had 1 year of follow-up data were eligible for inclusion in the study. According to the DEPAR protocol, patients provided clinical data and blood samples before treatment initiation and every 3 months thereafter. Minimal disease activity was defined according to the following parameters: swollen and tender joint counts 1; Leeds Enthesitis Index 1; Psoriasis Area Severity Index 1; patients global assessment by visual analog scale (VAS) 20 mm; patients pain assessment by VAS 15 mm; and Health Assessment Questionnaire 0.5. Serum cytokine concentrations were determined at baseline, 3 months, and 6 months using a bead-based immunoassay.

The study cohort included 219 patients (50% men), with mean age at enrollment of 5314 years. Overall, 183 patients (84%) were initiated with MTX monotherapy within 6 months of PsA diagnosis, of whom 49% remained on MTX monotherapy for 1 year. A total of 44 patients (24%) reached minimal disease activity at 6 months. At 1 year, 33 patients (18%) remained in minimal disease activity.

Compared with patients who had minimal disease activity at 1 year, patients who did not respond to treatment with MTX had higher mean baseline concentrations of IL-23 (17.444.78 vs 62.9425.02), tumor necrosis factor (2.630.66 vs 7.832.79), granulocyte-macrophage colony-stimulating factor (2.780.64 vs 6.52.07), interferon gamma (6.671.29 vs 19.746.85), and IL-10 (1.030.13 vs 2.080.6; all P <.05). Concentrations of IL-10 and IL-23 remained significantly higher among nonresponders at 6 months.

In this observational care cohort of patients with PsA, only 18% who were initiated on MTX remained in minimal disease activity at 1 year. Higher baseline and follow-up concentrations of IL-23 and IL-10 were observed in nonresponders. Further study is necessary to confirm the validity of these biomarkers for MTX response.

Study limitations included potential confounding factors and the need to validate the use of serum IL-23 as a therapy-response biomarker. Overall, conclusions about the effect of MTX therapy must be drawn with caution.

This study highlights the potential value of use of new tools, such as measuring cytokine profiles, to stratify patients for underlying driving pathogenic mechanisms of their disease, the investigators concluded.

den Braanker H, Wervers K, Mus AMC, et al. Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. RMD Open. 2020;6(2):e001175.

Follow this link:
Evaluating Methotrexate Monotherapy for Minimal Disease Activity Achievement in Early PsA - Rheumatology Advisor

The deformity can impair hand movement to the extent it limits daily activities severely, including self-care and employment, reducing health-related quality of life.

There are no approved treatments for the early stages of the disease and a high recurrence in late-stage disease when therapies including surgery and injection therapy which work for only a limited length of time.

Across the UK, the prevalence of the disease is approximately 20 per cent.

In Scotland the prevalence is much higher 40 per cent of the population - and in Scandinavian countries, it affects around 30 per cent of men over 60. This is because the disease is genetic; Scots are affected more than other parts of the UK because more people carry Celtic or Irish genes.

The drugs are: Cytokine inhibitors which has been used for treating rheumatoid and other forms of arthritis for around 15 years and JAK inhibitors which became available around five years ago, and is also used for the treatment of inflammatory arthritis.

Mr Millar said: Our work using patient samples from Dupuytrens Disease has discovered a key role for these drugs.

We were able to reverse these fibrotic changes in human cells. Until now, there has been nothing out there for these patients.

The two arthritis drugs are licensed for use in the treatment of that disease but under drug regulations, they must undergo further testing for use in the treatment of a different disease.

Mr Millar and his team have submitted a patent for the discovery of the new use of the drugs. They have also been awarded a grant from the Medical Research Council to conduct experimental therapeutic trials which he anticipates could start in a years time.

Retired teacher Andrew Tod from Edinburgh has lived with Dupuytrens Disease for the past 40 years and has undergone two operations on each hand.

He said: Anything that publicises this condition is going down the right lines.

I developed it without knowing what it was.

I just assumed like a pain in the ankle or something that it would just disappear and then it gradually got a little bit worse and a little bit worse in both hands.

So, that when I was working they would give me the nickname of the claw.

Basically it got worse and I did nothing about it - then I had two operations on one hand and two on the other.

To be honest it was really too late by that point.

I remember one of the surgeons asking me if Id ever heard of something called the bell curve?

It said my hands were off the radar for this measurement - so in other words I had neglected them all these years.

Theyre no better now but theyre no worse.

Ive got one finger on the left hand that works OK and one thats fine on the right, so typing is not a problem - I only use two fingers anyway. I can type and I can brush my teeth and perform the health measures.

My father had muscular dystrophy and I learnt from him that if you have a disability you have to adapt, it may take longer for you to do things but you just adapt.

Ive had no pain of any kind with it at all - all Ive had is inconvenience.

Im delighted theyve found drugs that could be effective and if someone gets the symptoms in their 30s and that means they can then be prepared for life as a professional pianist then splendid.

The condition is also known as the Curse of the MacCrimmons who were the 16th century pipers for the chieftains of Clan MacLeod on the Isle of Skye.

Folklore has it a curse was put on them for revealing piping secrets and it was foretold they would cease to be the official pipers to the MacLeods and would leave the Isle of Skye forever.

So, it came to pass. The fingers of the MacCrimmon men bent so far into their palms they became unable to play the bagpipes any more. Any piper who suffers from Dupuytrens Contracture as it is also known will tell you he has been affected by the Curse of the MacCrimmons.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.

By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

More here:
Arthritis drugs can cure hand deformity | Edinburgh News - East Lothian News

New Jersey, United States,- Latest update on Rheumatoid Arthritis Diagnostic Device Market Analysis report published with extensive market research, Rheumatoid Arthritis Diagnostic Device Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Rheumatoid Arthritis Diagnostic Device industry. With the classified Rheumatoid Arthritis Diagnostic Device market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Rheumatoid Arthritis Diagnostic Device market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Rheumatoid Arthritis Diagnostic Device market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Rheumatoid Arthritis Diagnostic Device Market growth opportunities in the industry.

Rheumatoid Arthritis Diagnostic Device Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Rheumatoid Arthritis Diagnostic Device market size, volume and value, as well as price data.

Rheumatoid Arthritis Diagnostic Device Market competition by top Manufacturers:

Rheumatoid Arthritis Diagnostic Device Market Classification by Types:

Rheumatoid Arthritis Diagnostic Device Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Rheumatoid Arthritis Diagnostic Device Market Report:

Cataloging the competitive terrain of the Rheumatoid Arthritis Diagnostic Device market:

Unveiling the geographical penetration of the Rheumatoid Arthritis Diagnostic Device market:

The report of the Rheumatoid Arthritis Diagnostic Device market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Rheumatoid Arthritis Diagnostic Device Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Rheumatoid Arthritis Diagnostic Device Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the article here:
Rheumatoid Arthritis Diagnostic Device Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast...

New Jersey, United States,- Latest update on Psoriatic Arthritis (PsA) Treatment Market Analysis report published with extensive market research, Psoriatic Arthritis (PsA) Treatment Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Psoriatic Arthritis (PsA) Treatment industry. With the classified Psoriatic Arthritis (PsA) Treatment market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Psoriatic Arthritis (PsA) Treatment market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Psoriatic Arthritis (PsA) Treatment market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Psoriatic Arthritis (PsA) Treatment Market growth opportunities in the industry.

Psoriatic Arthritis (PsA) Treatment Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Psoriatic Arthritis (PsA) Treatment market size, volume and value, as well as price data.

Psoriatic Arthritis (PsA) Treatment Market competition by top Manufacturers:

Psoriatic Arthritis (PsA) Treatment Market Classification by Types:

Psoriatic Arthritis (PsA) Treatment Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Psoriatic Arthritis (PsA) Treatment Market Report:

Cataloging the competitive terrain of the Psoriatic Arthritis (PsA) Treatment market:

Unveiling the geographical penetration of the Psoriatic Arthritis (PsA) Treatment market:

The report of the Psoriatic Arthritis (PsA) Treatment market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Psoriatic Arthritis (PsA) Treatment Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Psoriatic Arthritis (PsA) Treatment Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Go here to read the rest:
Psoriatic Arthritis (PsA) Treatment Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up...

Vijay Mohan

Tribune News Service

Chandigarh, July 12

Scientists from the Institute of Nano Science and Technology (INST), Mohali, have formulated nano-particles with a zinc-based compound that will help reduce the severity of rheumatoid arthritis.

The particles contain chitosan and zinc gluconate. Zinc is vital for maintaining normal bone homeostasis and its levels are reported to get reduced in rheumatoid arthritis patients. It is also known that oral supplementation of zinc in the form of zinc gluconate has very low bioavailability in humans.

Chitosan is a biocompatible, biodegradable natural polysaccharide (a carbohydrate whose molecules consist of a number of sugar molecules bonded together). It is one of the most abundant biopolymers obtained from the exoskeleton of crustaceans (crab, lobster, shrimp, etc) have shown absorption promoting characteristics.

The INST team particularly chose chitosan as it is biodegradable, biocompatible, non-toxic, and muco-adhesive in nature. A previously published report in the journal Magnesium Research exhibited that after intraperitoneal administration in rats, zinc oxide in standard form resulted in a slight increase in serum zinc level, whereas that in nano form resulted in significantly high serum zinc levels, thus increasing the zinc bioavailability. This motivated the INST team to develop the nanoformulation of zinc gluconate.

They prepared Zinc gluconate loaded chitosan nanoparticles using chitosan and sodium tripolyphosphate in double-distilled water and zinc gluconate was simultaneously added along with the synthesis of chitosan nanoparticles. These were characterised for various physicochemical properties and then anti-arthritic potential was investigated against collagen-induced arthritis in rats.

They observed that the treatment of rats with both zinc gluconate and zinc gluconate loaded chitosan nanoparticles reduced the severity of arthritis by reducing joint swelling, erythema, and edema.

The team assessed various parameters like biochemical analysis, histological observations, and immunohistochemical expression of inflammatory markers and suggested that zinc gluconate-loaded chitosan nanoparticles exerted superior therapeutic effects compared to the free form of zinc gluconate. This was attributed to the inflammatory potential of zinc gluconate-loaded chitosan nanoparticles.

Nanobiotechnology provides several effective solutions for the problems that traditional pharmaceutical formulations are often not able to address as effectively, such as sustained and targeted release of drugs, bioavailability, and efficacy of drugs and nutraceuticals, etc. The nanoformulation of zinc gluconate-loaded chitosan nanoparticles developed at INST Mohali is a creative example of a superior therapeutics for rheumatoid arthritis, said Prof Ashutosh Sharma, Secretary, Department of Science and Technology.

In the recent past, ionic gelation method has been widely employed for formulating chitosan nanoparticles, which may contain various medicinally active pharmacological agents.

Read the original here:
Mohali institute scientists formulate nanoparticle to reduce severity of rheumatoid arthritis - The Tribune India

In 2025, the market size of the Rheumatoid Arthritis Diagnosis Tests Market is expected to touch million US$ xx million. The revenue registered in 2018 was US$ xx million, thus depicting a growth at a CAGR of xx% from 2018. While in China, the market size was valued at US$ xx million in the forecast base year, further projected to increase up to US$ xx million till the end of 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Rheumatoid Arthritis Diagnosis Tests .

This report studies the global market size of Rheumatoid Arthritis Diagnosis Tests , especially focusing on the key regions such as United States, European Union, China, and other geographical extents (Japan, Korea, India, and Southeast Asia).

Request Sample Report @https://www.mrrse.com/sample/7491?source=atm

This study presents the Rheumatoid Arthritis Diagnosis Tests market production, revenue, market share, and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. The historical data breakdown for Rheumatoid Arthritis Diagnosis Tests for 2014-2018 is provided in the report along with company projection for 2018 to 2025.

For top companies in United States, European Union, and China, this report investigates and analyzes the production, value, price, market share, and growth rate for the manufacturers, key data from 2018 to 2025.

segmented as follows:

This report covers the global rheumatoid arthritis diagnosis tests market performance in terms of revenue contribution from various segments. This section also includes PMR analysis of key trends, drivers, restraints, and opportunities, which are influencing the growth of the global rheumatoid arthritis diagnosis tests market.

The global rheumatoid arthritis diagnosis tests market report begins with an overview of the global rheumatoid arthritis diagnosis tests market. This section also underlines factors influencing growth of the global rheumatoid arthritis diagnosis tests market along with detailing of the key trends, drivers, restraints, opportunity and regulations. Impact analysis of key regional growth drivers and restraints based on the weighted average model along with key region-specific trends is included in report to better equip clients with information and hidden insights.

The global rheumatoid arthritis diagnosis tests market is segmented on the basis of test type, end user and region. By test type, the global rheumatoid arthritis diagnosis tests market is segmented into serology test and monitoring RA treatment efficiency monitoring tests. Serology test segment is further sub-segmented into erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid test, and other tests. RA treatment efficiency monitoring tests segment is further sub-segmented into Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), and Creatinine Test. A detailed analysis has been provided for every segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractive index.

By end user, the global rheumatoid arthritis diagnosis tests market is segmented into hospital, diagnostic laboratories, and ambulatory surgical centers. Diagnostic laboratory segment is further sub-segmented into private laboratories and public laboratories. The next section of the report highlights the growth trends of the rheumatoid arthritis diagnosis tests market by region. It provides a market outlook for 20122027 and sets the forecast within the context of the rheumatoid arthritis diagnosis tests market. The study discusses key regional trends contributing to growth of the rheumatoid arthritis diagnosis tests market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. APAC region is expected to emerge dominant and most attractive over the forecast period.

The above sections test type, end user and region evaluate the present scenario and growth prospects of the rheumatoid arthritis diagnosis tests market for the period 20122027. We have considered 2016 as the base year and provided data for the forecast period.

The final chapter in the report covers analysis on key competitors involved in this market. Detailed company profiles include company-specific long-term and short-term strategies, key offerings and recent developments in the rheumatoid arthritis diagnosis tests market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/7491?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 describes Rheumatoid Arthritis Diagnosis Tests product/service scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2 profiles the top manufacturers of Rheumatoid Arthritis Diagnosis Tests market, with price, sales, revenue and global market share of Rheumatoid Arthritis Diagnosis Tests from 2014 2018.

Chapter 3 analyses the Rheumatoid Arthritis Diagnosis Tests competitive situation, sales, revenue. The global Rheumatoid Arthritis Diagnosis Tests market shares of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4 showcases the Rheumatoid Arthritis Diagnosis Tests breakdown data at the regional level, to discuss the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8, and 9 emphasize the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2014 to 2018.

Chapter 10 and 11 explain the segments by sales under type and application, with market shares and growth rate under each category, from 2014 to 2018.

Chapter 12 depicts Rheumatoid Arthritis Diagnosis Tests market forecasts by region, type, and application, with sales and revenue projections, from 2018 to 2025.

Chapter 13 and 14 describe Rheumatoid Arthritis Diagnosis Tests sales channel, distributors, customers, research findings and conclusion, appendix, and other data sources.

Buy This Report @ https://www.mrrse.com/checkout/7491?source=atm

Original post:
Rheumatoid Arthritis Diagnosis Tests Market Overview, Growth Opportunities, Industry Analysis, Size, Strategies and Forecast to 2026 - 3rd Watch News

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Seropositive Rheumatoid Arthritis DrugMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Seropositive Rheumatoid Arthritis Drug Market Players to battle Covid-19 Impact.

The Seropositive Rheumatoid Arthritis DrugMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. The research report gives the potential headway openings that prevails in the global market. It offers detailed research and analysis of key aspects of the Seropositive Rheumatoid Arthritis Drug market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Seropositive Rheumatoid Arthritis Drug market. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Seropositive Rheumatoid Arthritis Drug market include:Abbott Laboratories (U.S.), Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.) and More

Get PDF Sample Report With Full TOC, List of Tables & Figures, Chart @ https://www.marketinforeports.com/Market-Reports/Request-Sample/109877

Our Complimentary Sample Seropositive Rheumatoid Arthritis Drug market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets. The regional analysis section of the report offers a extensive analysis of the global Seropositive Rheumatoid Arthritis Drug market on the basis of region. The global Seropositive Rheumatoid Arthritis Drug market will showcase a steadyCAGR in the forecast year 2020 to 2025.

Type Segmentation:NsaidDmardsBiologics

Industry Segmentation:MedicineScientific Research

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/109877

Regions Covered in the Global Seropositive Rheumatoid Arthritis Drug Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Seropositive Rheumatoid Arthritis Drug Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

Key questions answered in the report:

For More Information:https://www.marketinforeports.com/Market-Reports/109877/Seropositive-Rheumatoid-Arthritis-Drug-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/109877/Seropositive-Rheumatoid-Arthritis-Drug-market

Contact Us:Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]Website: http://www.marketinforeports.com

View original post here:
Seropositive Rheumatoid Arthritis Drug Market 2025 Expected to reach Highest CAGR including major key players Abbott Laboratories (US), Johnson &...

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Rheumatoid Arthritis TherapeuticsMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Rheumatoid Arthritis Therapeutics Market Players to battle Covid-19 Impact.

The Rheumatoid Arthritis TherapeuticsMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. The research report gives the potential headway openings that prevails in the global market. It offers detailed research and analysis of key aspects of the Rheumatoid Arthritis Therapeutics market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Rheumatoid Arthritis Therapeutics market. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Rheumatoid Arthritis Therapeutics market include:AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche, UCB S.A., Johnson & Johnson Services, Amgen and More

Get PDF Sample Report With Full TOC, List of Tables & Figures, Chart @ https://www.marketinforeports.com/Market-Reports/Request-Sample/109865

Our Complimentary Sample Rheumatoid Arthritis Therapeutics market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets. The regional analysis section of the report offers a extensive analysis of the global Rheumatoid Arthritis Therapeutics market on the basis of region. The global Rheumatoid Arthritis Therapeutics market will showcase a steadyCAGR in the forecast year 2020 to 2025.

Type Segmentation:PharmaceuticalsBiopharmaceuticals

Industry Segmentation:PrescriptionOver-the-Counter (OTC)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/109865

Regions Covered in the Global Rheumatoid Arthritis Therapeutics Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Rheumatoid Arthritis Therapeutics Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

Key questions answered in the report:

For More Information:https://www.marketinforeports.com/Market-Reports/109865/Rheumatoid-Arthritis-Therapeutics-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/109865/Rheumatoid-Arthritis-Therapeutics-market

Contact Us:Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]Website: http://www.marketinforeports.com

View original post here:
COVID-19 Update: Global Rheumatoid Arthritis Therapeutics Market is Expected to Grow at a Healthy CAGR with top players AbbVie, Boehringer Ingelheim,...

Clinical trial result revealed that upadacitinib may be more effective in treating patients with rheumatoid arthritis than the gold standard of care, methotrexate.

Upadacitinib is a janus kinase (JAK) inhibitor that works to reduce inflammation caused by RA. It has been approved for treating patients with RA only after theyve tried methotrexate.

This trial convincingly demonstrates the efficacy of the JAK inhibitor upadacitinib as monotherapy in earlyrheumatoid arthritis. It works faster and better than methotrexate alone, said Ronald van Vollenhoven, MD, lead investigator for the trial.

Although methotrexate is the most widely accepted initial RA therapy, it achieves remission in a minority of patients and acceptable disease control in at most 60% of patients. Some patients may have insufficient initial responses or are intolerant to methotrexate. About 80% of patients will lose response over time and other medications such as disease-modifying antirheumatic drugs (DMARDs) are often added to treatment regimens to combat this.

The SELECT-EARLY trial enrolled 947 patients with early stage RA who were treatment nave to methotrexate. They were randomized to receive either 15 mg or 30 mg once daily of upadacitinib or weekly methotrexate for 24 weeks. Eighty-nine percent of enrolled patients completed the full 24 weeks.

The trial showed statistically significant and clinically meaningful improvements in both primary end points. Both doses of upadacitinib achieved a 50% response by week 12 (15 mg, 52%; 30 mg, 56%; P < .001) compared with methotrexate (28%; P < .001).

At week 24, 48% of patients receiving 15 mg upadacitinib and 50% of patients receiving 30 mg upadacitinib achieved a 28-joint Disease Activity Score of <2.6 compared with patients receiving methotrexate (19%, P < .001).

A significantly higher proportion of patients receiving either dose of upadacitinib compared to methotrexate also achieved low disease activity and remission by week 24 (15 mg: 24%; 95% CI, 20-29; 30 mg: 25%; 95% CI, 20-30; methotrexate: 7%; 95% CI, 4-10; P < .001).

Overall, 88% and 89% of patients receiving 15 mg or 30 mg of upadacitinib respectively had no radiographic progression. For patients receiving methotrexate, that number dropped to 78% (P < .01).

These head-to-head data provide consistent evidence of the efficacy of this JAK inhibitor versus the gold standard of initial RA therapy, supporting the potential of upadacitinib as a new therapeutic option for patients with RA, researchers said.

Additionally, the frequencies of treatment emergent adverse events (TEAEs) were similar between the 15 mg upadacitinib treatment arm and the methotrexate groups (65% vs 64%) but slightly higher in the upadacitinib 30mg treatment arm (71%).

Discontinuation due to TEAEs were comparable between all treatment arms (methotrexate: 5.1%; upadacitinib 15 mg: 4.4%; upadacitinib 30 mg: 3.8%).

A similar trend was observed for the frequency of serious adverse events. Acute myocardial infarction (methotrexate, n = 2; upadacitinib 30 mg, n = 1), pneumonia (methotrexate, n = 2; upadacitinib 15 mg, n = 1; upadacitinib 30 mg, n = 3), and osteoarthritis (upadacitinib 30 mg n = 2) were all reported in at least 1 patient in at least 1 treatment arm.

Development of serious infections such as pneumonia were higher among the upadacitinib 30 mg treatment arm and comparable between the 15 mg and the methotrexate treatment groups. A total of 6 deaths were reported. Two were from the 15 mg upadacitinib group, 3 from the 30 mg upadacitinib group, and 1 from the methotrexate group.

Excluding the difference in rate of side effects, the 30 mg dose of upadacitinib provided minimal additional benefit compared with the 15 mg dose.

Reference

van Vallenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-nave patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): A randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheum. July 8 2020. doi:10.1002/art.41384

Link:
Upadacitinib Proves to Be More Effective Than Methotrexate in Patients With RA - AJMC.com Managed Markets Network

A thorough study of the competitive landscape of the global Rheumatoid Arthritis Treatment Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This research report will give a clear idea to readers about the overall market scenario to further decide on this market projects.

The report analysis the leading players of the global Rheumatoid Arthritis Treatment market by inspecting their market share, recent developments, new product launches, partnerships, mergers, or acquisitions, and their target markets. This report also includes an exhaustive analysis of their product profiles to explore the products and applications their operations are concentrated on in the global Rheumatoid Arthritis Treatment market. Additionally, the report gives two distinct market forecasts, one from the perspective of the producer and another from that of the consumer. It also offers valuable recommendations for new as well as established players of the global Rheumatoid Arthritis Treatment market. It also provides beneficial insights for both new as well as established players of the global Rheumatoid Arthritis Treatment market.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

This report provides detailed historical analysis of global market for Rheumatoid Arthritis Treatment from 2014-2019, and provides extensive market forecasts from 2019-2025 by region country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Rheumatoid Arthritis Treatment market

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

The global Rheumatoid Arthritis Treatment market research is carried out at the different stages of the business lifecycle from the production of a product, cost, launch, application, consumption volume and sale. The research offers valuable insights into the marketplace from the beginning including some sound business plans chalked out by prominent market leaders to establish a strong foothold and expand their products into one thats better than others.

We provide detailed product mapping and investigation of various market scenarios. Our expert analysts provide a thorough analysis and breakdown of the market presence of key market leaders. We strive to stay updated with the recent developments and follow the latest company news related to the industry players operating in the global Rheumatoid Arthritis Treatment market. This helps us to comprehensively analysis the individual standing of the companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study to help you gain the upper hand in the competition.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-3119

Reasons why you should buy this report

Understand the current and future of the Rheumatoid Arthritis Treatment Market in both developed and emerging markets.

The report assists in realigning the business strategies by highlighting the Rheumatoid Arthritis Treatment business priorities.

The report throws light on the segment expected to dominate the Rheumatoid Arthritis Treatment industry and market.

Forecasts the regions expected to witness the fastest growth.

The latest developments in the Rheumatoid Arthritis Treatment industry and details of the industry leaders along with their market share and strategies.

Saves time on the entry level analysis because the report contains very important info regarding growth, size, leading players and segments of the business.

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Market.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-3119

Table of Contents

Report Overview: It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Rheumatoid Arthritis Treatment market segments by application, study objectives, and years considered.

Global Growth Trends: There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Rheumatoid Arthritis Treatment Market Share by Manufacturer: Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type: It includes analysis of price, production value market share, and production market share by type.

Market Size by Application: This section includes Rheumatoid Arthritis Treatment market consumption analysis by application.

Profiles of Manufacturers: Here, leading players of the global Rheumatoid Arthritis Treatment market are studied based on sales area, key products, gross margin, revenue, price, and production.

Rheumatoid Arthritis Treatment Market Value Chain and Sales Channel Analysis: It includes customer, distributor, Rheumatoid Arthritis Treatment market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

More here:
Surge in the Adoption of Rheumatoid Arthritis Treatment to Fuel the Growth of the Rheumatoid Arthritis Treatment Market Through the Assessment Period...

Wednesday, 8 July 2020, 2:38 pmPress Release: imsvet

In a twist on new uses of old things, Arthramid Vet isa unique and patented 2.5% cross-linked polyacrylamidehydrogel (PAAG) for intra-articular injection, and the firstPAAG in the world registered for veterinary use. Thisrevolutionary hydrogel contains no active pharmaceuticalingredient and is highly effective, safe and long-lasting.It has been used previously as a dermal filler in cosmeticsurgery but early indications are this new application couldone day even prevent joint damage.

Arthramid Vet isinjected into the joint of animals where it integrates intothe joint capsule of the diseased joint to provide abiocompatible tissue scaffold into which the bodys owntissues grow. This increases the elasticity, strength andstability of the joint resulting in reduced pain andlameness and improved joint function. The first negativeeffects of arthritis seen in a diseased joint.

Thefinal parts of the research conducted in NZ and Australiawere led by two NZ veterinarians and included collaborationwith Otago University and local labs to understand themechanism of action and safety of the product. The product,produced under license in Denmark, is now registered for usein horses in Australia and NZ and signals a move away fromanti inflammatories for managing this debilitatingdisease.

Furthermore, with the welfare of animals, andparticularly race horses, becoming a major focus forindustry groups the potential to reduce the use ofcorticosteroids is another significantbenefit.

Scoop Media

Become a member Find out more

Excerpt from:
NZ Vets Behind Major New Discovery In The Treatment Of Arthritis - Scoop.co.nz

Two abstracts presented at the European Hematology Association's annual meeting evaluatedthe frequency of myeloid malignancies in patients with autoimmune disease and the impact autoimmune diseases have on patients with sickle cell disease.

Researchers at the University of Pisa in Italy identified 55 patients in a retrospective systematic search through the electronic health records of patients between 2009 and 2019 with ADs and myeloid malignancies. Twenty (36%) patients had AD with myelodysplastic syndrome (MDS) and 35 (64%) had AD with MPNs.

In the group of patients with MPNs, 12 (34%) patients had chronic myeloid leukemia, 9 (26%) had myelofibrosis (MF), 8 (23%) had essential thrombocythemia (ET), and 6 (17%) had polycythemia vera (PV). In the MDS group, the most common diagnosis was anemia (16 patients, 80%).

In half of the patients with MDS, MDS occurred concurrently with the diagnosis of ADs, while MPNs generally preceded the diagnosis of ADs (19/35). The most common ADs among the MDS group were seronegative arthritis (25%), large and small vessel vasculitis (20%), and systemic lupus erythematosus (15%). In the MPN group, patients with MF were often associated with rheumatoid arthritis (22%) and antiphospholipid syndrome (33%), but patients with ET were more frequently detected to have anti-Ro52 (TRIM21)positive systemic connective tissue disorders (50%).

Overall, cardiovascular events were observed in 14 of the 55 patients (26%), and cardiovascular events were present in all patients with the JAK2 V617F mutation. This mutation was detected in 100%, 57%, and 66% of patients with PV, ET, and MF, respectively.

Our study shows that the frequency of MDS and MPNs in ADs is not negligible and might be considered in the assessment of cardiovascular risk in systemic autoimmunity, the authors concluded.

A second abstract evaluated the additional complications associated with ADs in patients with sickle cell disease (SCD).2 These researchers identified 40 patients enrolled in the Sickle Cell Disease Implementation Consortium who had AD. These patients with comorbid AD were slightly older than the average age of the remaining individuals in the registry (31 years vs 27.8 years).

Patients with SCD and AD had more frequent severe SCD complications compared with the patients in the registry with SCD alone. They also had greater incidence of the following conditions compared with patients with SCD alone:

Reference

1. Galimberti S, Barat C, Ricci F, et al. Clinical and biological features distinguish myeloid diseases from myeloid disorders associated with autoimmune diseases. Presented at: EHA25 2020; June 11-21, 2020; Abstract EP1076.

2. Kanter J, King A, Preiss L, Gordeuk V. Autoimmune disease is associated with greater risk of co-morbidity among teens and adults in the Sickle Cell Disease Implementation Consortium. Presented at: EHA25 2020; June 11-21, 2020; Abstract EP1529.

View post:
Assessing the Frequency and Impact of Autoimmune Diseases With Hematological Disorders - AJMC.com Managed Markets Network

Global Reactive Arthritis Treatment market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Reactive Arthritis Treatment .

This industry study presents the global Reactive Arthritis Treatment market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Reactive Arthritis Treatment market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-4982

Global Reactive Arthritis Treatment market report coverage:

The Reactive Arthritis Treatment market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Reactive Arthritis Treatment market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Reactive Arthritis Treatment market report:

Key Players

Some of the players in reactive arthritis treatment market includes F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Novartis AG, Amgen Inc., Velcura Therapeutics, Inc., Bayer AG, Geri-Care Pharmaceuticals, Merck Sharp & Dohme Corp, UCB S.A., Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, and AbbVie Inc., among others.

The report covers exhaustive analysis on:

The regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia-Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-4982

The study objectives are Reactive Arthritis Treatment Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-4982

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Reactive Arthritis Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Continued here:
High Focus on Product Innovation & Development to Assist the Growth of the Reactive Arthritis Treatment Market between and . 2017 2027 - 3rd...